Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

These growth stocks come from completely different industries, but each has something to offer long-term investors.

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...